Effect of Bushen Hemai decoction on vascular stiffness in elderly patients with isolated systolic hypertension

Objective: To investigate the effect of Bushen Hemai decoction on the wall stiffness of middle-aged and elderly patients with simple systolic hypertension. Methods: The 126 middle-aged and elderly patients with simple systolic hypertension admitted to our hospital from May 2010 to May 2015 were randomly divided into control group (63 cases) and observation group (63 cases). The control group was treated with conventional Western medicine, while the observation group was treated with Bushen Hemai decoction on the basis of the control group. The two groups were treated for 4 weeks. Results: The systolic blood pressure of the two groups decreased after treatment (observation group: T=16.165, control group: T=13.537, P<0.05);the systolic blood pressure of the two groups did not change significantly after treatment (observation group: T=1.857, control group: T=0.483, P>0.05);the systolic blood pressure of the observation group was lower than that of the control group after treatment (T=16.165, P<0.05). After treatment, the level of ST segment of ECG in the two groups was lower than that before treatment (observation group: T=22.145, control group: T=11.007, P<0.05);after treatment, the level of ST segment of ECG in the observation group was lower than that in the control group (T=8.130, P<0.05). After treatment, the pulse conduction velocity of the two groups was lower than that of the control group (observation group:T=8.694, control group: T=3.944, P<0.05);after treatment, the pulse conduction velocity of the observation group was lower than that of the control group (T=5.326, P<0.05). The total effective rate of the observation group (93.65%) was higher than that of the control group (76.19%) (P<0.05). Conclusion: Bushen Hemai Decoction has a significant clinical effect on middle-aged and elderly patients with simple systolic hypertension, and can improve the stiffness of the tube wall, which is worthy of clinical reference.

SGLT2i联合ARB对合并2型糖尿病的老年单纯收缩期高血压患者血压的影响分析

目的探讨钠-葡萄糖协同转运蛋白2抑制剂(sodium-dependent glucose transporter 2 inhibitor,SGLT2i)联合血管紧张素Ⅱ受体拮抗剂(angiotensinⅡreceptor blocker,ARB)对合并2型糖尿病的老年单纯收缩期高血压患者血压的影响。方法选取2019年9月至2022年9月于承德市中心医院心血管内科门诊就诊的合并2型糖尿病的老年单纯收缩期高血压患者150例为研究对象,根据随机数表法分为对照组(n=75)及实验组(n=75)。实验组采用厄贝沙坦150 mg/d联合达格列净10 mg/d口服治疗,对照组采用厄贝沙坦150 mg/d联合氢氯噻嗪12.5 mg/d口服治疗,对比两组治疗前后收缩压、脉压、平均动脉压、尿酸水平变化,分析两组肥胖改善率及治疗期间发生低钾血症和泌尿系感染的不良反应情况。结果治疗后,两组收缩压、脉压、平均动脉压均较治疗前降低且差异有统计学意义(P<0.05);在治疗12周后,实验组收缩压、脉压水平分别为(147.51±6.22)mmHg、(80.63±6.06)mmHg均低于对照组的(150.47±6.77)mmHg、(83.27±6.06)mmHg,差异具有统计学意义(P=0.006、P=0.008)。实验组肥胖改善率优于对照组(1 mmHg=0.133kPa),差异有统计学意义(P=0.034)。治疗期间实验组发生低钾血症概率低于对照组,差异有统计学意义(P=0.042)。结论SGLT2i联合ARB可有效降低合并2型糖尿病的老年单纯收缩期高血压患者的收缩压及脉压,且临床安全性可靠。

老年单纯性收缩期高血压的诊断和治疗进展

单纯性收缩期高血压(ISH)随着老龄化社会的进程而日渐受到关注,作为老年高血压的一种特殊亚型,对心脑血管均有严重的危害,积极控制ISH可以显著降低不良心血管事件的危险性。本文对ISH的诊疗进展进行了阐述。

补肾和脉方加减对中老年单纯收缩期高血压病患者管壁僵硬度的影响

目的:探讨中老年单纯收缩期高血压患者应用补肾和脉方加减治疗疗效以及对患者管壁僵硬度的影响。方法:按照随机表法将收治的126例中老年单纯收缩期高血压患者分为对照组63例与观察组63例。对照组采用常规西药治疗,观察组在对照组基础上结合补肾和脉方甲减治疗。两组疗程均为4周。比较两组治疗前后收缩压和舒张压变化、心电图ST段水平变化和脉搏传导速度变化及治疗疗效。结果:两组治疗后收缩压较治疗前降低(观察组:t=16.165,对照组:t=13.537,P<0.05);两组治疗后收缩压较治疗前无明显变化(观察组:t=1.857,对照组:t=0.483,P>0.05);观察组治疗后收缩压低于对照组(t=16.165,P<0.05)。两组治疗后心电图ST段水平较治疗前降低(观察组:t=22.145,对照组:t=11.007,P<0.05);观察组治疗后心电图ST段水平低于对照组(t=8.130,P<0.05)。两组治疗后脉搏传导速度较治疗前降低(观察组:t=8.694,对照组:t=3.944,P<0.05);观察组治疗后脉搏传导速度低于对照组(t=5.326,P<0.05)。观察组总有效率(93.65%)高于对照组(76.19%)(P<0.05)。结论:中老年单纯收缩期高血压患者应用补肾和脉方加减治疗疗效明显,且可使患者管壁僵硬度得以改善。

比索洛尔与地尔硫卓治疗老年单纯性收缩期高血压的降压疗效和安全性对比

目的分析比索洛尔与地尔硫卓治疗老年单纯性收缩期高血压的降压疗效和安全性。方法选取2020年1月至2021年3月本院收治的113例老年单纯性收缩期高血压患者作为研究对象,根据不同治疗方式分为3组,A组(n=38)采用比索洛尔治疗;B组(n=40)采用地尔硫卓治疗;C组(n=35)采用硝苯地平控释片治疗,比较3组治疗前后血压、心率和安全性。结果治疗前,3组收缩压、舒张压及心率比较差异无统计学意义;治疗后,3组血压和心率均低于治疗前,且C组收缩压、舒张压及心率均高于A组、B组,差异有统计学意义(P<0.05);A组、B组收缩压、舒张压及心率比较差异无统计学意义;3组不良反应发生率比较差异无统计学意义。结论采用比索洛尔及地尔硫卓治疗老年单纯性收缩期高血压患者,能有效降低患者血压和心率,临床疗效确切,但3种药物治疗的安全性无明显差异,在实际的临床治疗中,需根据患者的实际情况选择合适的治疗方案。